logo

Blood Disorder Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Global Bleeding Disorders Treatment Market Analysis and is segmented By Product Type (Plasma Derived Factors, Recombinant Factors, Others), By Application and Geography.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Circulatory System Drugs Research Bleeding Disorder Testing Market

Blood Disorder Therapeutics Market Size

bleeding disorders therapeutics market size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

bleeding disorders therapeutics market key players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Blood Disorder Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Blood Disorder Therapeutics Market Analysis

The Blood Disorder Therapeutics Market is expected to register a CAGR of 6.2% during the forecast period. Blood disorders are conditions that impact the blood's ability to function correctly. It includes problems with the white blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and the proteins which are involved in bleeding and clotting (hemostasis and thrombosis). Most of the blood disorders are caused by mutations in specific genes and can be passed down in families. According to the National Heart, Lung, and Blood Institute, Hemophilia A is the most common type of the disease in males then females about 1 in 4,000 to 1 in 5,000 males worldwide are born with Hemophilia A disorder and Hemophilia B occurs in approximately 1 in 20,000 newborn males worldwide. As per study published in the PLOS Medicine Journal, sickle cell anemia cases are expected to increase about 30 percent globally by the year 2050. Rising prevalence of various blood disorders and increasing investment in research and development for advance treatment options are the key driving factors in blood disorder therapeutics market.

Blood Disorder Therapeutics Market Trends

This section covers the major market trends shaping the Blood Disorder Therapeutics Market according to our research experts:

Recombinant Factors Segment is Expected to Hold a Significant Market Share in the Blood Disorder Therapeutics Market

  • Worldwide, the rising prevalence of blood disorders and increasing adoption of recombinant factor concentrates are the key drivers of the recombinant factors segment.
  • A recombinant factor is a form of blood factor that is manufactured via recombinant technology. Recombinant factors are used in the treatment of disorders such as hemophilia (prevention and control of hemorrhagic episodes).
  • According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by bleeding disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other bleeding disorders. Furthermore, according to the National Hemophilia Foundation, approximately 75% of people with hemophilia around the world still do not receive adequate treatment or have no access to treatment.
  • Recombinant factors segment hold a significant market share by revenue and is anticipated to show steady growth over the forecast period due to the growing need to treat blood-related disorders and increase in production of recombinant products globally.
bleeding disorders therapeutics market trends

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the blood disorder therapeutics market due to rising prevalence of various blood disorders and increasing awareness among the patient population in this region. According to the World Federation of Hemophilia, in the United States alone there are around 18 thousand people with hemophilia and over 11 thousand with von Willebrand disease. In addition, Hemophilia A affects 1 in 5,000 male births and approximately 400 babies are born with hemophilia A each year. Furthermore, increasing investments in research and development to develop treatment options for blood disorders and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

bleeding disorders therapeutics market analysis

Blood Disorder Therapeutics Industry Overview

The Blood Disorder Therapeutics  Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc, Amgen Inc and AstraZeneca Plc.

Blood Disorder Therapeutics Market Leaders

  1. Takeda Pharmaceutical Company Limited (Shire Plc)

  2. Sanofi

  3. Novo Nordisk A/S

  4. CSL Ltd

  5. Pfizer Inc

*Disclaimer: Major Players sorted in no particular order

Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc
Need More Details on Market Players and Competitors?
Download PDF

Blood Disorder Therapeutics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Various Blood Disorders

      2. 4.2.2 Increasing Investment in R&D for Advance Treatment Options

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Stringent Regulations Norms

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Plasma Derived Factors

      2. 5.1.2 Recombinant Factors

      3. 5.1.3 Other Products

    2. 5.2 By Application

      1. 5.2.1 Hemoglobin Diosrders

      2. 5.2.2 Platelet Based Disorders

      3. 5.2.3 Plasma Disorders

      4. 5.2.4 Myeloproliferative Disorders

      5. 5.2.5 Genetic Hematology Disorders

      6. 5.2.6 Blood Cancers

      7. 5.2.7 Other Application

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Takeda Pharmaceutical Company Limited (Shire Plc)

      2. 6.1.2 Sanofi

      3. 6.1.3 Novo Nordisk A/S

      4. 6.1.4 CSL Ltd

      5. 6.1.5 Pfizer Inc

      6. 6.1.6 Bayer AG

      7. 6.1.7 Celgene Corporation

      8. 6.1.8 Alexion Pharmaceuticals, Inc

      9. 6.1.9 Amgen Inc

      10. 6.1.10 AstraZeneca Plc

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Blood Disorder Therapeutics Industry Segmentation

Blood disorders are conditions that impact the blood's ability to function correctly. Most blood disorders decrease the number of platelets, proteins, nutrients or interfere with their function. Blood disorders covered under the market scope include anemia, bleeding disorders such as hemophilia, and blood cancers such as lymphoma, leukemia, and myeloma among others. Blood Disorder Therapeutics Market is segmented By Product Type, By Application and Geography.

By Product Type
Plasma Derived Factors
Recombinant Factors
Other Products
By Application
Hemoglobin Diosrders
Platelet Based Disorders
Plasma Disorders
Myeloproliferative Disorders
Genetic Hematology Disorders
Blood Cancers
Other Application
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Blood Disorder Therapeutics Market Research FAQs

The Blood Disorder Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)

Takeda Pharmaceutical Company Limited (Shire Plc) , Sanofi, Novo Nordisk A/S, CSL Ltd and Pfizer Inc are the major companies operating in the Blood Disorder Therapeutics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Blood Disorder Therapeutics Market.

The report covers the Blood Disorder Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Blood Disorder Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Dental Crowns and Bridges Industry Report

Statistics for the 2024 Dental Crowns and Bridges market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Dental Crowns and Bridges analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Bleeding Disorders Treatment Market Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Blood Disorder Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)